drugset / Trial / NCT01711333

A Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease

NCT01711333

Phase 4 Completed 101 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate symptomatic changes and safety before and after the administration of Pletaal® SR Capsules based on Peripheral Artery Questionnaire (PAQ) in subjects with peripheral arterial disease symptom due to chronic occlusive arterial disease (COAD).

Timeline

Start
2012-10-26
Primary completion
2014-05-20
Completion
2014-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg